Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (NCT07116499) titled 'A Phase IIa, Randomized, Double-Blind, Placebo-Controlled Study of K-645 in the Treatment of Multiple Migraine Attacks' on Aug. 7.

Study Type: Interventional

Study Design: Allocation: Randomized. Intervention model: Crossover Assignment. Primary purpose: Treatment. Masking: Triple (Participant, Investigator, Outcomes Assessor).

Primary Sponsor: Kallyope Inc.

Condition: Acute Migraine

Intervention: Drug: Placebo Drug: K-645 dose level 1

Recruitment Status: Recruiting

Phase: Phase 2

Date of First Enrollment: August 7, 2025

Target Sample Size: 120

Countries of Recruitment: United States

To know more, vis...